SBIR/STTR Research Award
AIT-082; A DRUG FOR TREATMENT OF ALZHEIMER'S DISEASE
Award amount
$478,811Program and phase
SBIR · Phase IIAward year
1993Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Advanced Immunotherapeutics
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
WE WILL DEVELOP AIT-082 FOR THE TREATMENT OF DEMENTIA DUE TO ALZHEIMER'S DISEASE, STROKE OR AGING. IN PHASE I, WE PLAN TO COMPLETE THE PRECLINICAL STUDIES NEEDED TO SUBMIT AN INVESTIGATION- AL NEW DRUG (IND) EXEMPTION APPLICATION TO THE FOOD AND DRUG ADMINISTRATION (FDA). SPECIFICALLY, WE WILL: (1) DETERMINE THE PRECLINICAL PHARMACODYNAMICS/ PHARMACOKINETICS OF AIT-082, (2) CONDUCT PRECLINICAL TOXICOLOGICAL TESTING, AND (3) CONDUCT ADDITIONAL PRECLINICAL STUDIES ON THE MECHANISM OF ACTION OF AIT- 082. THE AIM OF PHASE II WILL BE TO FILE AN IND APPLICATION AND TO ESTABLISH THE CLINICAL SAFETY AND EFFICACY OF AIT-082.
Technology keywords
Not reported